Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans
Alexander S. Banks, … , Domenico Accili, Paul B. Rothman
Alexander S. Banks, … , Domenico Accili, Paul B. Rothman
Published September 1, 2005
Citation Information: J Clin Invest. 2005;115(9):2462-2471. https://doi.org/10.1172/JCI23853.
View: Text | PDF
Research Article Metabolism

Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans

  • Text
  • PDF
Abstract

NIDDM is characterized by progressive insulin resistance and the failure of insulin-producing pancreatic β cells to compensate for this resistance. Hyperinsulinemia, inflammation, and prolonged activation of the insulin receptor (INSR) have been shown to induce insulin resistance by decreasing INSR substrate (IRS) protein levels. Here we describe a role for SOCS7 in regulating insulin signaling. Socs7-deficient mice exhibited lower glucose levels and prolonged hypoglycemia during an insulin tolerance test and increased glucose clearance in a glucose tolerance test. Six-month-old Socs7-deficient mice exhibited increased growth of pancreatic islets with mildly increased fasting insulin levels and hypoglycemia. These defects correlated with increased IRS protein levels and enhanced insulin action in cells lacking SOCS7. Additionally, SOCS7 associated with the INSR and IRS1 — molecules that are essential for normal regulation of insulin action. These data suggest that SOCS7 is a potent regulator of glucose homeostasis and insulin signaling.

Authors

Alexander S. Banks, Jianze Li, Lisa McKeag, Marta L. Hribal, Masaki Kashiwada, Domenico Accili, Paul B. Rothman

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Socs7 affects insulin signaling and IRS1 protein stability. (A) Insulin ...
Socs7 affects insulin signaling and IRS1 protein stability. (A) Insulin stimulation of wild-type or Socs7 –/ – mice. Six-week-old female mice were injected with a 5-unit bolus of human insulin. Soleus muscle was harvested at the times indicated. IRS1 tyrosine phosphorylation (p-Tyr) was assayed by immunoprecipitation and immunoblot. The blots were stripped and reprobed for IRS1 to assess protein loading. Relative molecular weight markers are indicated in kDa. (B) Schematic representation of SOCS7 mutants. Wild-type SOCS7 contains 4 polyproline domains (P), an SH2 domain, and a SOCS box domain (SB). The ΔN mutant lacks the 4 N-terminal polyproline domains. The ΔSB mutant contains a deletion of the C-terminal SOCS box. The R→K mutation includes 2 point mutations in the phosphotyrosine-binding domain of the SH2 domain. (C) HEK293 cells were transfected with cDNAs for ubiquitin, Irs1, and wild-type or mutant Socs7 as indicated. Forty-eight hours after transfection, cells were harvested, and immunoprecipitation and immunoblotting for IRS1 were performed. (D) HEK293 cells were transfected as in C. Then, 42 hours after transfection, cells were preincubated for 30 minutes with either 20 μM of the proteasome inhibitor MG132 (right 3 lanes) or methanol carrier as a control. Cells were then stimulated with 100 nM insulin for 6 hours before harvest and immunoprecipitation with IRS1 and immunoblot with anti-ubiquitin antibody. Whole cell lysates were blotted with an antibody recognizing SOCS7. IRS1-Ub, ubiquitinated IRS1.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts